CA2022610A1 - Proteine gp130 humaine - Google Patents

Proteine gp130 humaine

Info

Publication number
CA2022610A1
CA2022610A1 CA2022610A CA2022610A CA2022610A1 CA 2022610 A1 CA2022610 A1 CA 2022610A1 CA 2022610 A CA2022610 A CA 2022610A CA 2022610 A CA2022610 A CA 2022610A CA 2022610 A1 CA2022610 A1 CA 2022610A1
Authority
CA
Canada
Prior art keywords
protein
human
interleukin
receptor
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2022610A
Other languages
English (en)
Other versions
CA2022610C (fr
Inventor
Tadamitsu Kishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2022610A1 publication Critical patent/CA2022610A1/fr
Application granted granted Critical
Publication of CA2022610C publication Critical patent/CA2022610C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002022610A 1989-08-03 1990-08-02 Proteine gp130 humaine Expired - Lifetime CA2022610C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP20023089 1989-08-03
JP01-200230 1989-08-03
JP2140069A JP2898064B2 (ja) 1989-08-03 1990-05-31 ヒトｇｐ１３０蛋白質
JP02-140069 1990-05-31

Publications (2)

Publication Number Publication Date
CA2022610A1 true CA2022610A1 (fr) 1991-02-04
CA2022610C CA2022610C (fr) 2001-01-30

Family

ID=26472699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002022610A Expired - Lifetime CA2022610C (fr) 1989-08-03 1990-08-02 Proteine gp130 humaine

Country Status (10)

Country Link
US (1) US5132403A (fr)
EP (1) EP0411946B1 (fr)
JP (1) JP2898064B2 (fr)
KR (1) KR0178384B1 (fr)
AT (1) ATE147099T1 (fr)
AU (1) AU635296B2 (fr)
CA (1) CA2022610C (fr)
DE (1) DE69029545T2 (fr)
ES (1) ES2096580T3 (fr)
IL (1) IL95235A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE194086T1 (de) * 1991-12-18 2000-07-15 Icu Medical Inc Medizinisches ventil
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
US5789552A (en) * 1993-06-23 1998-08-04 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
ATE169161T1 (de) * 1994-06-23 1998-08-15 Elin Ebg Motoren Gmbh Kühlung für einen motor
GB9419021D0 (en) 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
JP3458512B2 (ja) 1995-02-23 2003-10-20 東ソー株式会社 骨密度の変動推定方法又は骨そしょう症の診断方法及びこれに用いる試薬キット
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
KR19990022359A (ko) * 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 시토킨 시그날 트랜스듀서 ｇｐ130 ｍＲＮＡ에 특이적인 올리고뉴클레오티드
EP0869176A4 (fr) * 1995-11-07 2000-09-20 Kaneka Corp Autoantigenes
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
EP2135953B1 (fr) 1999-06-02 2014-04-23 Chugai Seiyaku Kabushiki Kaisha Protéine réceptrice d'hémopoïétine, Nr. 10
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
DE60025241T2 (de) 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB0210539D0 (en) * 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2625773C (fr) 2005-10-14 2015-05-12 Fukuoka University Inhibition du recepteur de l'interleukin-6 (il-6) favorisant la transplantation d'ilots pancreatiques
JP4837358B2 (ja) * 2005-10-19 2011-12-14 株式会社野村工電社 ボトル飲用水充填装置
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (fr) 2005-11-25 2012-06-06 Keio University Agent thérapeutique pour le cancer de la prostate
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2123302B1 (fr) 2007-01-23 2015-12-09 Shinshu University Inhibiteurs de il-6 pour le traitement de rejet chronique
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
EP2226633A1 (fr) 2009-03-06 2010-09-08 Charité - Universitätsmedizin Berlin Utilisations et procédés d'identification d'un composé cytoprotecteur impliquant gp130 ou LIFRalpha
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
EP2417162A2 (fr) 2009-04-10 2012-02-15 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre l'il-6r et polypeptides les comprenant pour le traitement des maladies et des troubles liés à l'il-6r
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
DK2578231T3 (da) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd Antitumor-t-celle-reaktionsforstærker
EP2747782B1 (fr) 2011-09-23 2018-01-17 Ablynx NV Inhibition prolongée d'une signalisation à médiation par l'interleukine-6
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP3209327A1 (fr) 2014-10-21 2017-08-30 Ablynx N.V. Traitement de maladies associées à il-6r
CN107249637A (zh) 2015-02-27 2017-10-13 中外制药株式会社 用于治疗il‑6相关疾病的组合物
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
KR102351174B1 (ko) * 2020-05-11 2022-01-14 (주)아이테오솔루션즈 랜 포트의 혼동을 방지하는 어댑터 및 이를 포함하는 랜 포트 보안 장치
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드

Also Published As

Publication number Publication date
EP0411946B1 (fr) 1997-01-02
IL95235A (en) 1995-11-27
JPH0429997A (ja) 1992-01-31
ATE147099T1 (de) 1997-01-15
KR0178384B1 (ko) 1999-04-01
EP0411946A2 (fr) 1991-02-06
IL95235A0 (en) 1991-06-10
AU6003990A (en) 1991-02-07
EP0411946A3 (en) 1992-02-12
US5132403A (en) 1992-07-21
AU635296B2 (en) 1993-03-18
DE69029545T2 (de) 1997-07-24
DE69029545D1 (de) 1997-02-13
CA2022610C (fr) 2001-01-30
ES2096580T3 (es) 1997-03-16
JP2898064B2 (ja) 1999-05-31
KR910004801A (ko) 1991-03-29

Similar Documents

Publication Publication Date Title
CA2022610A1 (fr) Proteine gp130 humaine
AU7087891A (en) Modified hil-6
CA2114015A1 (fr) Anticorps recombinants pour la therapie humaine
CA2021528A1 (fr) Muteines de l'erythropoietine humaine, leur preparation et leur utilisation
AU8007087A (en) New forms of colony stimulating factor-1
AU7165287A (en) DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
EP0219106A3 (fr) Polypeptides induisant des anticorps contre le virus du SIDA
AU639226B2 (en) Recombinant protein receptor
ES2017122A6 (es) Procedimiento de preparacion de proteina de ligado de heparina.
AU625866B2 (en) Soluble interferon-gamma receptors and methods for their production
AU2179688A (en) Recombinant eukaryotic cells production interleukin-2, process and vectors for their preparation and process for the preparation of interleukin-2
IE890577L (en) Expression of hiv binding proteins
IL92685A0 (en) Dna encoding lymphokine/cytokine like proteins,cells transformed thereby and production of said proteins and antibodies against them
AU5627090A (en) A novel alpha-amylase-pullulanase enzyme, a dna sequence coding the same, a recombinant dna molecule and a recombinant clone expressing the enzyme
DE3561719D1 (en) Process for the preparation of symmetrical benzophenones substituted by fluor-containing groups, their use and symmetrical benzophenones substituted by fluor-containing groups
EP0237676A3 (fr) Toxine de ricine recombinante
AU7734687A (en) Novel substituted (4.2.0.)bicyclooctane derivatives with valuable therapeutic properties
EP0343132A3 (en) Methods and systems for producing hiv antigens
AU1072588A (en) Cycloalkane (1,2-c:4,3-c') dipyrazoles
GB2199830B (en) Recombinant plasmid dna pvn22, coding for biosynthesis of human leukocyte interferon -i1 and strain pseudomonas sp. 31 (pvn22)
EP0333691A3 (fr) Protéine de fusion recombinante, son utilisation et vecteur recombinant
Jian Written Speech
IL77152A0 (en) Expression vectors for protein production in e.coli and their production
GB2210373A (en) Recombinant plasmid dna ppr-il2-19,coding for synthsis of human interleukin-2 and strain of bacteria escherichia coli vniigenetika vl 903 (ppr-il2-19)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry